Dr Maximillian Hochmair discussed about the head-to-head comparison trials on efficacy and safety of different EGFR-TKI as well as the clinical benefits of prescribing afatinib as first-line then followed by osimertinib in patients who acquired EGFR resistance mutation T790M.